Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14762165 | 0.76 | GAA (0.45) | ALDH1A1GAAHSD17B10MEN1LMNA | |
| SCHEMBL9666642 | 0.75 | ALDH1A1 (0.43) | ALDH1A1GAAHSD17B10LMNAMAPT | |
| SCHEMBL14283780 | 0.75 | ALOX15 (0.40) | ALDH1A1CGASGAAHSD17B10MEN1 | |
| Bromide SCHEMBL9548958 | 0.73 | ALDH1A1 (0.42) | ALDH1A1GAAHSD17B10LMNAMAPT | |
| SCHEMBL3324059 | 0.70 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL24925369 | 0.70 | KDM4E (0.33) | ALDH1A1GAAHSD17B10HPGDKDM4E | |
| SCHEMBL24253573 | 0.70 | CGAS (0.30) | ALDH1A1CGASGAAHPGDKDM4E | |
| SCHEMBL24403156 | 0.67 | CYP1A2 (0.47) | ALDH1A1GAAMEN1MAPTHPGD | |
| SCHEMBL24924715 | 0.66 | ALDH1A1 (0.49) | ALDH1A1GAAHSD17B10MEN1LMNA | |
| SCHEMBL14772212 | 0.66 | TRPA1 (0.47) | ALDH1A1GAAMEN1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | ALDH1A1 4181/4885CGAS 1591/4885GAA 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.